• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dominari Holdings Inc. Releases Shareholder Update

    9/6/23 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DOMH alert in real time by email

    NEW YORK, Sept. 6, 2023 /PRNewswire/ -- Dominari Holdings Inc. ("Dominari" or the "Company") today released the following shareholder update:

    This organization chart illustrates our current structure, where the shaded entities denote plans for future growth.

    Dear Fellow Shareholders,

    As disclosed in prior letters and filings, Dominari has completed its transition from a drug development company to a financial services company, complete with a fully registered and rapidly growing broker-dealer subsidiary.  With the first full quarter of operating a broker-dealer behind us, I am excited to take this opportunity to update you on our business and provide you with additional insights on how we intend to grow moving forward.

    Recent Accomplishments

    With our recent acquisitions, we currently hold over $700 million in client assets.  We will continue to aggressively seek to grow the business through the acquisition of other wealth management teams with assets under management.  Additionally, our budding capital markets team has already enjoyed success across a broad spectrum of industries, including in healthcare, biotechnology, industrial and consumer industries. To date, we have participated in more than 24 follow-on public offerings including public offerings in ImmunoGen, Rexford Industrial, ANI Pharmaceuticals, Inc., Agilon health, Maxeon Solar Technologies, Ltd., Gates Industrial, Celestica, and GE HealthCare.  Additionally, we have acted as co-manager on two initial public offerings (IPOs). Finally, our capital markets team was successful in raising money for two pre-IPO special purpose vehicles and we expect to be actively involved in any future IPOs for such companies if they materialize.  Lastly, we are looking to grow our financial advisory business which has already started to generate fee revenue for the Company.

    The Path Forward

    As demonstrated above, we will continue to create a unique blend of traditional wealth management offerings that clients have come to know and trust.  In addition, we are creating opportunities for our clients to participate in the leading edge of wealth creation vehicles via our access to pre-IPO companies and other unique alternative financial investments.

    We are committed to becoming a leading full-service diversified financial services firm, with multiple pillars of growth and revenue. Building on our early success, we will continue to develop  a solid recurring revenue, fee-based Registered Investment Advisor (RIA) model, which will enable us to derive revenue from fees deposits and the lending that often occurs from these deposits. In addition and consistent with our activities to date, we plan to offer:

    • Traditional investment banking activities such as IPOs, equity capital markets and mergers and acquisitions advisory.
    • Alternative investment activities, which will be focused on pre-IPO activity, private placements, special purpose vehicles (SPVs) and gaining access to top private equity funds, venture capital (VC) funds and hedge funds for our clientele.

    Our leadership team is comprised of many seasoned veterans from leading Wall Street firms.  We are building on this experienced team to recruit top talent, from the wire houses and various RIAs and smaller broker dealers that don't have access to the desired offerings we have created under one umbrella. It is our belief that many financial advisors have become disenfranchised with the larger and more restrictive wire houses and there is a movement towards independent providers. While many of the independents do not offer a breadth of wire house services, we hope to offer an even better solution for financial advisors. Our elite custodial and clearing agreements enable us to offer all the capabilities of the more traditional wire houses yet remain fiercely independent and help propel forward the independent culture, which has been attractive to so many advisors over the last decade. We believe that with our access to investment banking, equity capital markets and Pre-IPOs, along with our cutting edge fintech partnerships, such as Addepar, we will offer an unparalleled solution to an entrepreneurial-minded advisor, which in turn, will offer a second to none experience for their clientele. 

    As for Company structure, we have placed all of the legacy AikidoPharma business into a subsidiary, Aikido Labs LLC.  Aikido Labs will continue to monitor and monetize the assets formerly held by AikidoPharma, such as the biotechnology assets and the Company'sholdings in other companies.  We believe that several of these other holdings may go public in the next six (6) months.  When they do, we will look to use the proceeds from any liquidity event to bolster and potentially expand Dominari Financial.  Currently, under Dominari Financial, we have placed Dominari Securities.  Our plans are to expand the entities under Dominari Financial to include Dominari Asset Management that will focus on exchange traded funds and mutual funds, as well as an insurance business.  We believe this structure will allow us to better service our clients with a full suite of financial services.

    This organization chart illustrates our current structure, where the shaded entities denote plans for future growth:

    Management strongly believes that the Company has created a solid platform from which to grow. As evidenced by our publicly filed Form 4s, members of the management team made multiple stock purchase transactions throughout the first, second and third quarters to demonstrate our belief in the Company.  The percentage of stock owned by senior management exceeds eighteen percent (18%) of the total stock issued and outstanding.  

    We thank you for being a Dominari shareholder. As always, please feel free to reach out if you have any questions.

    Warm Regards,

    Anthony Hayes

    Chief Executive Officer

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, which include but are not limited to the Risk Factors set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 relating to its business. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Contact:

    Investor Relations    

    Hayden IR

    Brett Maas, Managing Partner

    Phone: (646) 536-7331

    Email: [email protected]

    www.haydenir.com

    Dominari Holdings Logo (PRNewsfoto/Dominari Holdings Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dominari-holdings-inc-releases-shareholder-update-301918877.html

    SOURCE Dominari Holdings Inc.

    Get the next $DOMH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DOMH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DOMH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dominari Holdings Issues Letter to Shareholders

    NEW YORK, Jan. 28, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today issued the following letter to shareholders: I am pleased to report that 2025 was a transformative and highly successful year for Dominari. Through disciplined execution, expanded distribution capabilities, and a focus on high-growth opportunities across both public and private markets, we delivered strong financial performance and created substantive shareholder value. Shareholder Value Creation As we began 2025, the Company's stock price was just over $1.00. When

    1/28/26 8:30:00 AM ET
    $DOMH
    $TZUP
    $UMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology

    Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend

    NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that, following its press release issued on December 11, 2025, the board of directors has updated the record date and payment date for the previously announced special cash dividend of approximately $10 million, or approximately $0.44 per share. The dividend is now payable on or about January 26, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on January 5, 2026. For additional informatio

    12/12/25 5:45:00 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Announces $10 Million Cash Dividend

    NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that its board of directors has authorized a special cash dividend of, in the aggregate, approximately $10 million, or approximately $0.44 per share.  The dividend is payable on or about January 23, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on December 31, 2025. For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/ About Dominari Ho

    12/11/25 7:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: CEO Hayes Anthony bought $89,054 worth of shares (23,000 units at $3.87), increasing direct ownership by 1% to 1,750,873 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:22:01 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President Wool Kyle Michael bought $96,798 worth of shares (25,000 units at $3.87), increasing direct ownership by 2% to 1,211,828 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:20:35 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Wool Kyle Michael decreased direct ownership by 1% to 2,453,817 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 7:54:17 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    SEC Filings

    View All

    SEC Form DEF 14A filed by Dominari Holdings Inc.

    DEF 14A - Dominari Holdings Inc. (0000012239) (Filer)

    2/6/26 11:32:26 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Dominari Holdings Inc.

    PRE 14A - Dominari Holdings Inc. (0000012239) (Filer)

    1/26/26 5:11:28 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Dominari Holdings Inc.

    S-8 - Dominari Holdings Inc. (0000012239) (Filer)

    1/8/26 7:55:26 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    COO Devall Christopher Franklin was granted 10,000 shares, increasing direct ownership by 7% to 155,702 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/12/25 9:48:09 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: CEO Hayes Anthony bought $89,054 worth of shares (23,000 units at $3.87), increasing direct ownership by 1% to 1,750,873 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:22:01 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President Wool Kyle Michael bought $96,798 worth of shares (25,000 units at $3.87), increasing direct ownership by 2% to 1,211,828 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:20:35 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Leadership Updates

    Live Leadership Updates

    View All

    Dominari Expands Strategic Leadership with Appointment of Ambassador Jamie McCourt to Advisory Board

    Dominari Withdraws $2 Billion Shelf Registration NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today announced a major enhancement to its strategic leadership with the appointment of Ambassador Jamie McCourt to the Advisory Board of Dominari Securities. Separately, the company has formally withdrawn its previously filed $2 billion shelf registration statement, reflecting confidence in its financial position and growth outlook. Globally recognized diplomat, executive and entrepreneur Ambassador Jamie McCourt Joins Advisory Board Ambassador McCourt

    12/8/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Receives Approval as a Limited Underwriting Member of the New York Stock Exchange

    Enables direct participation in underwriting activities conducted through NYSE and NYSEAmerican platforms NEW YORK, Oct. 9, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today announced that its wholly owned subsidiary, Dominari Securities LLC, has been approved as a Limited Underwriting member of the New York Stock Exchange and NYSE American Equities (the "Exchanges") effective October 8, 2025. This approval marks an important regulatory milestone for Dominari Securities as it continues to expand its capabilities within U.S. capital m

    10/9/25 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Appoints Communications and Growth Strategist Brian Parsley to Board

    Accomplished entrepreneur and global speaker to strengthen firm's marketing, investor engagement and strategic communications to help drive growth NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH), today announced the appointment of Brian Parsley to its Board of Directors. Parsley, an accomplished entrepreneur, behavioral analyst and internationally recognized speaker, will support the firm's growth by enhancing its marketing, investor outreach and overall communications strategy. Mr. Parsley has more than 30 years of experience in entrepreneurship,

    9/10/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Financials

    Live finance-specific insights

    View All

    Dominari Holdings Issues Letter to Shareholders

    NEW YORK, Jan. 28, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today issued the following letter to shareholders: I am pleased to report that 2025 was a transformative and highly successful year for Dominari. Through disciplined execution, expanded distribution capabilities, and a focus on high-growth opportunities across both public and private markets, we delivered strong financial performance and created substantive shareholder value. Shareholder Value Creation As we began 2025, the Company's stock price was just over $1.00. When

    1/28/26 8:30:00 AM ET
    $DOMH
    $TZUP
    $UMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology

    Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend

    NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that, following its press release issued on December 11, 2025, the board of directors has updated the record date and payment date for the previously announced special cash dividend of approximately $10 million, or approximately $0.44 per share. The dividend is now payable on or about January 26, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on January 5, 2026. For additional informatio

    12/12/25 5:45:00 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Announces $10 Million Cash Dividend

    NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that its board of directors has authorized a special cash dividend of, in the aggregate, approximately $10 million, or approximately $0.44 per share.  The dividend is payable on or about January 23, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on December 31, 2025. For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/ About Dominari Ho

    12/11/25 7:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 8:56:04 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 4:32:07 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care